Latest News

A pharmacy technician reflects on 3 patient encounters that reshaped his understanding of what a real patient requires.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.

Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.

Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.

ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.

ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.

A cohort study linked higher BMI and abdominal obesity to increased cancer risk in young adults, reinforcing the importance of early weight management.

Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.

Study shows prior authorization and high out-of-pocket costs drive prescription abandonment, limiting Medicare Part D blood cancer treatment access to oral anticancer medications.

A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.

From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.

Every-12-week immune checkpoint inhibitor dosing failed to establish noninferiority in the phase 3 MOIO trial, with an overall survival imbalance and no meaningful safety advantage over standard treatment.

Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.

From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.